Description
Sofosbuvir is an antiviral compound that inhibits viral RNA polymerase. Sofosbuvir is clinically used to treat hepatitis C infection. This compound is a prodrug that is metabolized to a more active intermediate.
Sofosbuvir
Product ID S5722
Cas No. 1190307-88-0
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 1190307-88-0 |
|---|---|
| Purity | ≥98% |
| Formula | C22H29FN3O9P |
| Formula Wt. | 529.45 |
| IUPAC Name | propan-2-yl (2S)-2-[[[(2R,3R,4R,5R)-5-(2,4-dioxopyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyloxolan-2-yl]methoxy-phenoxyphosphoryl]amino]propanoate |
| Solubility | DMSO 100 mg/mL warmed (188.87 mM) Ethanol 100 mg/mL (188.87 mM) Water 11 mg/mL warmed (20.77 mM) |
| Appearance | Yellow to off white powder |
Shipping and Storage
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Murakami C, Melda Urekli H, Atta MG. Antiviral medications for the treatment of hepatitis B and C infection and their effects on kidney function. Minerva Gastroenterol Dietol. 2014 Sep;60(3):177-89. PMID: 25027705.
Fung A, Jin Z, Dyatkina N, et al. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother. 2014 Jul;58(7):3636-45. PMID: 24733478.
Murakami E, Tolstykh T, Bao H, et al. Mechanism of activation of PSI-7851 and its diastereoisomer PSI-7977. J Biol Chem. 2010 Nov 5;285(45):34337-47. PMID: 20801890.